M Pierre Pang, MD
Ophthalmology · Honolulu, HINPI 1487654794
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,064 of the $9,673 with a category attached, or 83.4%. It is spread thinly across 26 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations.
Across 317 payments — averaging $30.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$2K
- AbbVie$1K
- Alcon$1K
- Novartis$921
- Sun Pharmaceutical Industries Inc.$906
- Bausch & Lomb Americas Inc.$440
- plus $3K from 20 others
What the payments were for
- Travel & lodging$1,60917%
- Food & beverage$8,06483%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 16 | $2,073 |
| AbbVie(2 entities) | 54 | $1,279 |
| Alcon | 25 | $1,262 |
| Novartis | 53 | $921 |
| Sun Pharmaceutical Industries Inc. | 33 | $906 |
| Bausch & Lomb Americas Inc. | 18 | $440 |
| Aerie Pharmaceuticals, Inc. | 21 | $404 |
| Amgen(2 entities) | 19 | $391 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 15 | $362 |
| Kala Pharmaceuticals, Inc. | 14 | $303 |
| Regeneron Healthcare Solutions, Inc. | 12 | $254 |
| Oyster Point Pharma, Inc. | 8 | $197 |
| Harrow Eye, LLC | 2 | $161 |
| Tarsus Pharmaceuticals, Inc. | 5 | $114 |
| Genentech USA, Inc. | 6 | $105 |
| Regeneron | 1 | $104 |
| Dompe US, Inc. | 3 | $87 |
| Glaukos Corporation | 2 | $71 |
| Mallinckrodt Hospital Products Inc. | 2 | $51 |
| Eyepoint US, Inc. | 1 | $44 |
| Sight Sciences, Inc. | 2 | $30 |
| Biogen | 1 | $27 |
| Mallinckrodt Enterprises LLC | 1 | $25 |
| Astellas Pharma US Inc | 1 | $24 |
| Shire North American Group Inc | 1 | $23 |
| Eyevance Pharmaceuticals LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis 1-piece IOL$1,724
- Tecnis Multifocal Family of 1-piece IOLS$1,724
- Tecnis Symfony IOL$1,724
- Unity$276
- VYZULTA$247
- Clareon PanOptix Pro$146
- ARGOS$146
- Clareon$145
- DURYSTA$123
- XEN GLAUCOMA TREATMENT SYSTEM$123
- EYLEA$104
- EYLEA HD$104
How this compares
$9,673 in reported general payments places this provider in the 75th percentile of 120 ophthalmology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 67 | $98,313 |
| XiidraLifitegrast | 44 | $73,946 |
| Alphagan PBrimonidine Tartrate | 41 | $21,277 |
| VyzultaLatanoprostene Bunod | 37 | $17,875 |
| ProlensaBromfenac Sodium | 45 | $16,910 |
| Brimonidine Tartrate | 125 | $15,262 |
| LumiganBimatoprost | 31 | $14,912 |
| CombiganBrimonidine Tartrate/Timolol | 36 | $14,842 |
| RocklatanNetarsudil Mesylat/Latanoprost | 25 | $11,826 |
| TyrvayaVarenicline Tartrate | 11 | $9,761 |
| Prednisolone Acetate | 156 | $7,793 |
| Bromfenac Sodium | 35 | $6,459 |
| Cyclosporine | 11 | $5,653 |
| Timolol Maleate | 140 | $3,312 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 11 | $2,851 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Alphagan P, Lumigan, Combigan | $1,279 | $149,345175 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $440 | $91,82181 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $362 | $16,91045 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $404 | $11,82625 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $197 | $9,76111 claims |
| AlconSimbrinza | $1,262 | $2,85111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 120 ophthalmology providers in Hawaii.
Other ophthalmology in Honolulu
- Neda NikpoorHonolulu$293K
- Carlton YuenHonolulu$175K
- Alan FaulknerHonolulu$135K
- Michael BennettHonolulu$108K
- Jeffrey PetersonHonolulu$77K
- Rupa WongHonolulu$72K
- Jon PortisHonolulu$20K
- Tyrie JenkinsHonolulu$19K
- John OlkowskiHonolulu$15K
- Claudia HootenHonolulu$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.